1-硝基-4-(2,2,3,3,3-五氟丙氧基)苯 | 109230-70-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-硝基-4-(2,2,3,3,3-五氟丙氧基)苯
• 英文名称: 1-nitro-4-(2,2,3,3,3-pentafluoropropoxy)benzene
• 英文别名: 4-(2,2,3,3,3-Pentafluoropropoxy)-1-nitrobenzene
• CAS: 109230-70-8
• 化学式: C₉H₆F₅NO₃
• 分子量: 271.144
• InChiKey: UOOGKSSUBKFORQ-UHFFFAOYSA-N

物化性质

• 熔点：
  51-54 °C
• 沸点：
  265.0±40.0 °C(Predicted)
• 密度：
  1.460±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  1-硝基-4-(2,2,3,3,3-五氟丙氧基)苯 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 以100%的产率得到4-(2,2,3,3,3-pentafluoropropoxy)phenylamine
  参考文献：
  名称：

  Optically Active Antifungal Azoles. VI. Synthesis and Antifungal Activity of N-((1R,2R)-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl)-N'-(4-substituted phenyl)-3(2H,4H)-1,2,4-triazolones and 5(1H,4H)-tetrazolones.

  摘要：

  通过(1S)-1-[(2R)-2-(2,4-二氟苯基)-2-环氧乙烷基]乙醇的三氟甲磺酸酯衍生物与一种吖唑酮阴离子经SN2取代反应及随后与1H-1,2,4-三氮唑的开环反应制备了一系列具有光学活性的新型抗真菌唑类化合物，N-[(1R,2R)-2-(2,4-二氟苯基)-2-羟基-1-甲基-3-(1H-1,2,4-三唑-1-基)丙基]-N'-(4-取代苯基)-3(2H,4H)-1,2,4-三唑酮(1,2)和5(1H,4H)-四唑酮(3)。手性环氧乙烷乙醇13是以立体控制方式由甲基(R)-乳酸制得。所制得的吖唑酮1-3在体外及体内均展现出强大的抗真菌活性。

  DOI：

  10.1248/cpb.44.314
• 作为产物：
  描述：

  2,2,3,3,3-五氟-1-丙醇 、 对硝基氯苯 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 30.0h， 生成 1-硝基-4-(2,2,3,3,3-五氟丙氧基)苯
  参考文献：
  名称：

  Optically Active Antifungal Azoles. VI. Synthesis and Antifungal Activity of N-((1R,2R)-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl)-N'-(4-substituted phenyl)-3(2H,4H)-1,2,4-triazolones and 5(1H,4H)-tetrazolones.

  摘要：

  通过(1S)-1-[(2R)-2-(2,4-二氟苯基)-2-环氧乙烷基]乙醇的三氟甲磺酸酯衍生物与一种吖唑酮阴离子经SN2取代反应及随后与1H-1,2,4-三氮唑的开环反应制备了一系列具有光学活性的新型抗真菌唑类化合物，N-[(1R,2R)-2-(2,4-二氟苯基)-2-羟基-1-甲基-3-(1H-1,2,4-三唑-1-基)丙基]-N'-(4-取代苯基)-3(2H,4H)-1,2,4-三唑酮(1,2)和5(1H,4H)-四唑酮(3)。手性环氧乙烷乙醇13是以立体控制方式由甲基(R)-乳酸制得。所制得的吖唑酮1-3在体外及体内均展现出强大的抗真菌活性。

  DOI：

  10.1248/cpb.44.314

文献信息

• Fused ring compound and use thereof
  申请人：Suzuki Hideo

  公开号：US20100190747A1

  公开（公告）日：2010-07-29

  The present invention provides a compound represented by the formula: wherein the symbols are as described in the specification, or a salt thereof, which is useful for preventing/treating eicosanoid-associated diseases such as atherosclerosis, diabetes, obesity, atherothrombosis, asthma, fever, pain, cancer, rheumatism, osteoarthritis and atopic dermatitis, and which has an excellent pharmacological action, physicochemical properties, etc.

  本发明提供一种化合物，其化学式如下： 其中符号如规范中所述，或其盐，用于预防/治疗与前列腺素相关的疾病，如动脉粥样硬化、糖尿病、肥胖、动脉血栓形成、哮喘、发热、疼痛、癌症、风湿病、骨关节炎和特应性皮炎等，并具有优异的药理作用、理化性质等。
• Optically Active Antifungal Azoles. VI. Synthesis and Antifungal Activity of N-((1R,2R)-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl)-N'-(4-substituted phenyl)-3(2H,4H)-1,2,4-triazolones and 5(1H,4H)-tetrazolones.
  作者：Tomoyuki KITAZAKI、Norikazu TAMURA、Akihiro TASAKA、Yoshihiro MATSUSHITA、Ryogo HAYASHI、Kenji OKONOGI、Katsumi ITOH

  DOI：10.1248/cpb.44.314

  日期：——

  A new series of optically active antifungal azoles, N-[(1R, 2R)-2-(2, 4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1, 2, 4-triazol-1-yl)propyl]-N'-(4-substituted phenyl)-3(2H, 4H)-1, 2, 4-triazolones (1, 2) and 5(1H, 4H)-tetrazolones (3), were prepared from the triflate derivative of (1S)-1-[(2R)-2-(2, 4-difluorophenyl)-2-oxiranyl]ethanol (13) by an SN2 displacement reaction with the anion of an azolone (17-19) and subsequent ring-opening reaction with 1H-1, 2, 4-triazole. The optically active oxiranylethanol 13 was synthesized from methyl (R)-lactate in a stereo-controlled manner. The azolones 1-3 prepared showed potent antifungal activities in vitro and in vivo.

  通过(1S)-1-[(2R)-2-(2,4-二氟苯基)-2-环氧乙烷基]乙醇的三氟甲磺酸酯衍生物与一种吖唑酮阴离子经SN2取代反应及随后与1H-1,2,4-三氮唑的开环反应制备了一系列具有光学活性的新型抗真菌唑类化合物，N-[(1R,2R)-2-(2,4-二氟苯基)-2-羟基-1-甲基-3-(1H-1,2,4-三唑-1-基)丙基]-N'-(4-取代苯基)-3(2H,4H)-1,2,4-三唑酮(1,2)和5(1H,4H)-四唑酮(3)。手性环氧乙烷乙醇13是以立体控制方式由甲基(R)-乳酸制得。所制得的吖唑酮1-3在体外及体内均展现出强大的抗真菌活性。
• Amide inhibitors of leukotriene A4 hydrolase
  申请人：Chen Ming

  公开号：US20070155727A1

  公开（公告）日：2007-07-05

  This invention is directed to compounds of formula (I): where r, q, R, R 2 , R 3 , R 4a , R 4b , R 4c , R 5a , R 5b , R 5c , R 6a , R 6b , R 6c , R 7 , R 8 , R 9 and R 10 are described herein, or pharmaceutically acceptable salts, solvates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A 4 hydrolase inhibitors and which are therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of using and preparing the compounds of the invention are also disclosed.

  本发明涉及的化合物的化学式为（I）：其中r、q、R、R2、R3、R4a、R4b、R4c、R5a、R5b、R5c、R6a、R6b、R6c、R7、R8、R9和R10如本文所述，或其药学上可接受的盐、溶剂化合物、多晶形、铵离子、N-氧化物或其前药；这些化合物是白三烯A4水解酶抑制剂，因此在治疗炎症性疾病方面具有用途。本发明还涉及包含所述化合物的药物组合物以及使用和制备所述化合物的方法。
• INHIBITORS OF LEUKOTRIENE A4 HYDROLASE
  申请人：Celtaxsys, Inc.

  公开号：US20160068534A1

  公开（公告）日：2016-03-10

  The present invention is directed to compounds encompassed by the Formula (I), pharmaceutical compositions thereof, methods for inhibiting LTA-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of LTA4 h activity. Non-limiting examples of such diseases and conditions include inflammatory and autoimmune diseases and disorders.

  本发明涉及公式（I）所包含的化合物，其制药组合物，抑制LTA-4水解酶的方法，以及通过抑制LTA4h活性治疗疾病和疾病的方法和治疗疾病和疾病的方法。此类疾病和状况的非限制性示例包括炎症和自身免疫性疾病和疾病。
• Inhibitors of leukotriene A4 hydrolase
  申请人：CELTAXSYS, INC.

  公开号：US10399986B2

  公开（公告）日：2019-09-03

  The present invention is directed to compounds encompassed by the Formula (I): pharmaceutical compositions thereof, methods for inhibiting LTA-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of LTA4h activity. Non-limiting examples of such diseases and conditions include inflammatory and autoimmune diseases and disorders.

  本发明涉及式 (I) 所包含的化合物： 其药物组合物、抑制LTA-4水解酶的方法，以及治疗通过抑制LTA4h活性而得到改善的疾病和紊乱的方法。此类疾病和病症的非限制性实例包括炎症性和自身免疫性疾病和病症。